Search - tctmd.com

Displaying 1 - 20 of 36

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2023

Shelley Wood

November 30, 2023

Looking for a Winner Between Long-term TAVI Trials? Don’t, Experts Urge

Shelley Wood

November 27, 2023

News Conference News TCT 2023

Post-TAVI Conduction Abnormalities: EP Study, Registry Data Provide Snapshots

Caitlin E. Cox

November 03, 2023

News Conference News TCT 2023

Durability, Hemodynamics Look Good for SAVR, TAVI in PARTNER 3

Michael O'Riordan

November 01, 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2023

Shelley Wood

November 01, 2023

News Conference News TCT 2023

VIVA: No Difference Between TAVI and SAVR for Small Aortic Annuli

L.A. McKeown

October 27, 2023

Presentation TCT 2023

TCT 906: Leaflet Thrombosis in a patient with Severe, Bicuspid Aortic Valve Stenosis and Severely Depressed LVEF: Acute Leaflet Thrombosis Less than 24 Hours After Evolut R Implantation

Presenter: Fabio Enrique Posas

October 26, 2023

Presentation TCT 2023

TCT 386: Sapien 3 in Degenerated Calcified Evolut: Assessing Hydrodynamic Function and Leaflet Kinematics After Redo-TAVR

Presenter: Janarthanan Sathananthan

October 25, 2023

Presentation TCT 2023

TCT 954: High Risk Left Main Stenting through EVOLUT Valve with Impella Support from Axillary Access

Presenter: Sze Jia Ng

October 25, 2023

Presentation TCT 2023

Optimizing Outcomes With Self-Expanding Valves: The OPTIMIZE PRO Study and Evolut PRO Plus and FX Valves

Presenter: Steven Yakubov

October 25, 2023

Presentation TCT 2023

TCT 248: Assessment of Coronary Cannulation, Commissure and Coronary Alignment post TAVR with the New Supra-Annular, Self-Expanding Evolut FX System

Presenter: Guilherme Attizzani

October 25, 2023

Presentation TCT 2023

TCT 519: Coronary access and percutaneous coronary intervention feasibility after transcatheter aortic valve replacement in failed bioprosthetic valves with ACURATE neo2 versus Evolut PRO+

Presenter: Francesco Giannini

October 25, 2023

News Conference News TCT 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

Michael O'Riordan

October 24, 2023

Presentation TCT 2023

TCT 383: Feasibility of TAV-in-TAV in Evolut valves using in-vivo CT sizing and its impact on coronary obstruction and patient prosthesis mismatch

Presenter: Atsushi Okada

October 24, 2023

Presentation TCT 2023

TCT 133: Reinterventions After CoreValve/Evolut Transcatheter or Surgical Aortic Valve Replacement for Treatment of Severe Aortic Stenosis

Presenter: Kendra Grubb

October 24, 2023

Presentation TCT 2023

Four-Year Outcomes From the EVOLUT Low Risk Trial

Presenter: Michael Reardon

October 24, 2023

News Daily News

SAVR 5-Year Survival Tops 92% in Low-Risk Patients: STS Registry

Yael L. Maxwell

October 20, 2023

News Opinion Editor's Corner

What’s Going to Be Hot at TCT 2023

Shelley Wood

October 19, 2023

News Daily News

US Cardiologists’ Pay, Productivity Held Steady in 2022: MedAxiom Survey

Caitlin E. Cox

October 16, 2023

News Conference News EACTS 2023

AUTHEARTVISIT Reignites RCT vs Real-world Data Debate for AV Repair

Michael O'Riordan

October 09, 2023

Advertisement

TCTMD’s Top 10 Most Popular Stories for November 2023

Looking for a Winner Between Long-term TAVI Trials? Don’t, Experts Urge

Post-TAVI Conduction Abnormalities: EP Study, Registry Data Provide Snapshots

Durability, Hemodynamics Look Good for SAVR, TAVI in PARTNER 3

TCTMD’s Top 10 Most Popular Stories for October 2023

VIVA: No Difference Between TAVI and SAVR for Small Aortic Annuli

TCT 906: Leaflet Thrombosis in a patient with Severe, Bicuspid Aortic Valve Stenosis and Severely Depressed LVEF: Acute Leaflet Thrombosis Less than 24 Hours After Evolut R Implantation

TCT 386: Sapien 3 in Degenerated Calcified Evolut: Assessing Hydrodynamic Function and Leaflet Kinematics After Redo-TAVR

TCT 954: High Risk Left Main Stenting through EVOLUT Valve with Impella Support from Axillary Access

Optimizing Outcomes With Self-Expanding Valves: The OPTIMIZE PRO Study and Evolut PRO Plus and FX Valves

TCT 248: Assessment of Coronary Cannulation, Commissure and Coronary Alignment post TAVR with the New Supra-Annular, Self-Expanding Evolut FX System

TCT 519: Coronary access and percutaneous coronary intervention feasibility after transcatheter aortic valve replacement in failed bioprosthetic valves with ACURATE neo2 versus Evolut PRO+

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

TCT 383: Feasibility of TAV-in-TAV in Evolut valves using in-vivo CT sizing and its impact on coronary obstruction and patient prosthesis mismatch

TCT 133: Reinterventions After CoreValve/Evolut Transcatheter or Surgical Aortic Valve Replacement for Treatment of Severe Aortic Stenosis

Four-Year Outcomes From the EVOLUT Low Risk Trial

SAVR 5-Year Survival Tops 92% in Low-Risk Patients: STS Registry

What’s Going to Be Hot at TCT 2023

US Cardiologists’ Pay, Productivity Held Steady in 2022: MedAxiom Survey

AUTHEARTVISIT Reignites RCT vs Real-world Data Debate for AV Repair

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content